"The promise of medicine in the post-genomic world is still as exciting as ever," declares Don Drakeman, CEO of Medarex Inc. , but he reckons that "probably some of the early industry-wide enthusiasm for mapping the genome and getting new targets slid over a lot of blocking and tackling that has to be done." As head of a company leveraging rights to basic means of producing therapeutic antibodies, Drakeman is on the front line, trying to move forward into a space that is still coming into being.
Like Abgenix Inc. , which effectively shares a duopoly with Medarex on technology for making mice with human immune...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?